CARLSBAD, California, May 11, 2017 /PRNewswire/ -- Applied Spectral Imaging (ASI), a global leader of computer-assisted
PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in determining the treatment for patients with non-small cell lung cancer (NSCLC), the most common type of cancer which accounts for 13% of the total number of cancer cases in the US. The significant success of PD-1/PD-L1 blockades in lung cancer has led to the FDA approval of revolutionary immunotherapy drugs, and PD-L1 assays are becoming standard care for all patients with a suspected lung cancer.
HiPath, ASI's flagship system for advanced IHC imaging and analysis, is a pioneer in digital pathology solutions that support PD-L1 analysis, for research use. It determines PD-L1 protein expression by calculating the percentage of viable tumour cells showing partial or complete membrane staining, and automatically provides the tumor proportion score (TPS).ASI's CEO, Limor Shiposh, commented: "We are committed to being at the forefront of innovation, through continuous development of valuable technological solutions that help pathologists provide the best patient care possible."
HiPath provides digital automation of IHC tissue analysis. It allows pathologists to capture images, receive computer-aided scoring, and generate automatic reports with complete case statistics. HiPath provides accurate, reproducible and standardized results, while integrating seamlessly with pathologists' existing microscope and workflow. It is FDA cleared for ER, PR, HER2/neu, and Ki-67, yet supports all nuclear and membrane stains.
ASI is a global leader in the development of imaging solutions, supporting fluorescent, brightfield and spectral image-acquisition, for pathology tests, FISH and karyotyping.
The HiPath™ and GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.
ASI's applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.
ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.
For More Information Please Contact:
Applied Spectral Imaging Phone: +1-(760)-929-2840E-mail: firstname.lastname@example.org www.appliedspectralimaging.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asis-hipath-for-computer-assisted-pd-l1-interpretation-300456002.html
SOURCE Applied Spectral Imaging (ASI)
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All